Physician profile
Lynn Baru
NPI 1972529055
$6,102.57
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,396 · 2020: $393 · 2021: $314.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $4,215.15 | 2019 | |
| Tandem Diabetes Care, INC. | $312.33 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $239.00 | 2019-2021 | |
| Novo Nordisk INC | $180.79 | 2019-2020 | |
| Amgen INC. | $158.93 | 2019-2020 | |
| Insulet Corporation | $152.36 | 2019 | |
| Dexcom, INC. | $143.51 | 2019-2021 | |
| Lilly USA, LLC | $137.89 | 2019-2021 | |
| Abbott Laboratories | $100.56 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.20 | 2019-2021 | |
| Abbvie INC. | $53.96 | 2019-2021 | |
| Shire North American Group INC | $40.98 | 2019 | |
| Xeris Pharmaceuticals, INC. | $35.91 | 2020 | |
| Amarin Pharma, INC. | $32.37 | 2019 | |
| Becton, Dickinson and Company | $26.38 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $25.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.42 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.71 | 2021 | |
| Recordati_rare_diseases_inc. | $19.49 | 2021 | |
| Merck Sharp & Dohme LLC | $15.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.37 | 2020 | |
| Valeritas, INC. | $14.13 | 2019 | |
| Lifescan, INC. | $13.75 | 2019 | |
| Vivus LLC | $12.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$1,197.25 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Baru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.